Accessibility Menu
Akeso logo

Akeso(SEHK) 9926

Market CapHK$87.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)+292%
5 Year+128%
1 Year-42%
1 Month-4%
HK$89.90
-5.72%
-5.45Today
Akeso last closing stock price
MetricPriceDate
Last closeHKD 89.902026-08-31
Akeso stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.75%HKD 88.352026-08-24
1 month-4.31%HKD 93.952026-07-31
3 month-15.59%HKD 106.502026-06-02
Year to date-20.44%HKD 113.002025-12-31
1 year-42.26%HKD 155.702025-08-29
3 year+160.96%HKD 34.452023-08-31
5 year+127.59%HKD 39.502021-09-01
Since inception+292.39%HKD 24.302020-04-24

Akeso Financials at a Glance

Market Cap

HK$87.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥5.91B

Net Income (TTM)

-CN¥1.80B

EPS (TTM)

-HK$1.18

P/E Ratio

-80.89

Dividend

HK$0.00

Beta (Volatility)

-0.06 (Low)

Price

HK$89.90

Volume

14,098,740

Open

HK$95.35

Previous Close

HK$95.35

Daily Range

HK$89.60 - HK$95.35

52-Week Range

HK$80.20 - HK$159.80

Estimated Earnings Date

Mar 31, 2027

9926 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Akeso

Akeso, Inc. is a biopharmaceutical enterprise focused on the discovery, development, manufacturing, and commercialization of therapeutic solutions, particularly in oncology. The company has a diverse pipeline, including innovative treatments for various malignancies and other medical conditions.

Products and Services
  • AK104: A PD-1/CTLA-4 bi-specific antibody for multiple cancers
  • AK112: Targets PD-1/VEGF for solid and gynecological tumors
  • AK120: An IL-4R monoclonal antibody for atopic dermatitis and asthma
Growth Outlook
  • Strong focus on oncology with multiple candidates in late-stage development
  • Collaborations with major partners like Pfizer and AstraZeneca enhance market reach
  • Increasing demand for innovative cancer therapies supports long-term growth potential
Financial Highlights
  • Recent quarterly revenue of CNY 1.62 billion, showing significant growth
  • Gross profit margin of 78% indicates strong product demand and pricing power
  • Current ratio of 5.14 suggests robust liquidity position for operational needs
Akeso, Inc. operates in a competitive biotechnology sector, emphasizing innovative cancer therapies. The company's diverse product pipeline, including bi-specific antibodies and monoclonal antibodies, positions it well for future growth. Recent financial performance indicates a strong revenue trajectory, with a notable gross profit margin reflecting effective cost management and product demand. Collaborations with established pharmaceutical companies further enhance Akeso's market presence and development capabilities. The company's solid liquidity position, as indicated by a current ratio of 5.14, provides a strong foundation for ongoing research and development efforts. Overall, Akeso, Inc. presents a compelling opportunity within the biotechnology landscape, particularly for investors interested in oncology-focused therapeutic solutions.
AI Generated • Aug 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3,761

CEO

Michelle Xia, PhD

Website

www.akesobio.com/en

Headquarters

Zhongshan, GD 528437, CN

9926 Financials

Key Financial Metrics (TTM)

Gross Margin

76.04%

Operating Margin

-22.35%

Net Income Margin

-28.02%

Return on Equity

-10.86%

Return on Capital

-6.75%

Return on Assets

-5.87%

Earnings Yield

-1.24%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$87.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

919.97M

Volume

14.10M

Avg. Volume

14.48M

Financials (TTM)

Gross Profit

CN¥4.60B

Operating Income

-CN¥1.46B

EBITDA

-CN¥1.35B

Operating Cash Flow

-CN¥969.59M

Capital Expenditure

-CN¥522.93M

Free Cash Flow

-CN¥1.01B

Cash & ST Invst.

CN¥9.16B

Total Debt

CN¥994.35M

Akeso Performance Analysis

Akeso annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 997,495,986266.8%
20232023-12-31CNY 5,004,966,879401.8%
20242024-12-31CNY 2,302,830,725-54.0%
20252025-12-31CNY 3,314,601,66543.9%
Akeso sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-317.3%
Q22025-06-3028.4%
Q42025-12-3114.6%
Q22026-06-3010.1%
Akeso annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -1.653.7%
20232023-12-31CNY 2.68N/A
20242024-12-31CNY -0.66N/A
20252025-12-31CNY -1.34104.0%
Akeso sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-14.3%
Q22025-06-30-100.0%
Q42025-12-319.4%
Q22026-06-3020.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥1.78B

+73.8%

Gross Profit

CN¥1.32B

+41.0%

Gross Margin

74.24%

N/A

Market Cap

HK$87.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$23.32M

N/A

Employees

3,761

N/A

Net Income

-CN¥418.36M

-75.3%

EBITDA

-CN¥278.51M

+8.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥9.16B

+207.6%

Total Debt

CN¥994.35M

-70.0%

Accounts Receivable

CN¥966.18M

+108.5%

Inventory

CN¥1.10B

+120.8%

Long Term Debt

CN¥4.00B

+31.9%

Short Term Debt

CN¥993.18M

+247.9%

Return on Assets

-5.87%

N/A

Return on Invested Capital

-5.69%

N/A

Free Cash Flow

CN¥290.28M

+149.1%

Operating Cash Flow

CN¥290.28M

+183.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 9926

What is the current price of Akeso?

Akeso is trading at HK$89.90 per share.

What is the 52-week range for Akeso?

Over the past 52 weeks, Akeso has traded between HK$80.20 and HK$159.80.

How much debt does Akeso have?

As of the most recent reporting period, Akeso reported total debt of CN¥5.07B.

How much cash does Akeso have on hand?

Akeso reported CN¥1.47B in cash and cash equivalents in its most recent financial results.

What is Akeso’s dividend yield?

Akeso does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services